Trial · NCT06506084
Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)
NCT06506084, Recruiting, FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV). Trials, record NCT06506084. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06506084
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)
- NCT number
- NCT06506084
- Status
- Recruiting
- Enrollment
- 429 participants, estimated
- Lead sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- Conditions
- Polycythemia Vera
- Interventions
- Ropeginterferon alfa-2b
- First posted
- 2024-07-17
- Last updated
- 2026-07-09
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete hematological remission (CHR)* after 1 and 2 years of treatment. | At baseline and during the follow up at 6/12/18/24 months per patient. | \*HCT lower than 45% without phlebotomies in the past 3 months; platelet count ≤ 400x109/L, WBC count \<10 x109/L |
| Secondary | Screening failure | At baseline and during the follow up at 6/12/18/24 months per patient. | Percentage of patients who, after careful screening as required in good clinical practice, will fail the indications for concomitant clinical or laboratory abnormalities. |
| Secondary | Complete hematological (CHR) and clinical remission (CR) after 1 and 2 years of treatment stratified by different eligibility categories for treatment indication. | At baseline and during the follow up at 6/12/18/24 months per patient. | Secondary Outcomes for efficacy |
| Secondary | Dose-response effect on CHR and CR | At baseline and during the follow up at 6/12/18/24 months per patient. | Secondary Outcomes for efficacy |
| Secondary | Frequency of phlebotomies | At baseline and during the follow up at 6/12/18/24 months per patient. | Secondary Outcomes for efficacy |
| Secondary | Change in spleen size | At baseline and during the follow up at 6/12/18/24 months per patient. | Change in spleen size (from baseline) evaluated by palpation. |
| Secondary | Incidence of any of the following: o arterial and venous thrombotic events; o hemorrhagic events; o disease related symptoms; o disease evolutions into myelofibrosis and acute leukemia; o secondary malignancies. | At baseline and during the follow up at 6/12/18/24 months per patient. | Secondary Outcomes for efficacy |
| Secondary | Incidence, causality and intensity of any adverse event occurring during study period (as defined by MedDRA code and graded according to Common Terminology Criteria for Adverse Events (CTCAE last version)). | At baseline and during the follow up at 6/12/18/24 months per patient. | Secondary Outcomes for safety |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06506084
GET https://conductscience.org/api/trials/v1/NCT06506084/registered